All Blogs
Jul 14, 2022
Zsquare ENT-Flex Rhinolaryngoscope Receives FDA Clearance; ClearMind Biomedical’s Completion of Least Invasive ICH Treatment; Bruker Launched Tool for ‘Long COVID’ Multi-Organ Risk Assessment; EarlySign, Roche Signed Strategic Deal; FDA Clearance for Leva® Pelvic Health System; NeuroOne’s Evo® sEEG Electrode
Zsquare ENT-Flex™ Rhinolaryngoscope, the First High-Performance Single-Use ENT Endoscope of Zsquare received FDA Clearance On July 06, 2022, Zsquare, one of the leading developers of high-performance, single-use endoscopes, received Food and Drug Administration 510K clearance to market its first product, the Zsq...
Read More...
Jul 13, 2022
Role of Seizures Alert and Monitoring Devices in the Management of Epilepsy
As per the WHO, roughly 50 million people worldwide have Epilepsy. The burden of Epilepsy is growing in almost every geographic region. According to the Global Burden of Disease report on the burden of neurological diseases, it is observed that idiopathic epilepsy accounted for 5% of all neurological DALYs and 1.3%...
Read More...
Jul 12, 2022
Novo Nordisk’s Concizumab for Hemophilia; AbbVie Ends its Alliance with Alector; ADC Therapeutics and Sobi Enters in Exclusive Licensing Deal; BMS’ Opdivo Gets NHS Use; Merck to Acquire Seagen; FDA Priority Review to Roche’s Lunsumio; AstraZeneca to Acquire TeneoTwo; FDA Orphan Drug Designation to PBI-200
Novo Nordisk Reports Phase III Results of Concizumab Drug for Hemophilia A or B Novo Nordisk has announced Phase III results for their concizumab drug for hemophilia A or B, demonstrating efficacy in preventing bleeding events and paving the way for regulatory filings later this year. Concizumab, an anti-tissue ...
Read More...
Jul 08, 2022
Comprehensive Assessment of the Leading Companies in the Vaccines Market
Millions of lives are saved annually all because of vaccination, which is a success story in global health and development. More than 20 life-threatening diseases can now be prevented with vaccines, allowing individuals of all ages to live longer, healthier lives. Vaccines prevent 3.5–5 million deaths yearly from d...
Read More...
Jul 07, 2022
Collagen Matrix FDA 510(k) approval for Fibrillar Collagen Wound Dressing; Roche’s cancer diagnostics ULTRA PLUS system launch; Insightec IDE Approval for Prostate Cancer; JustLight plc. trial of Sunflower Rx for Alzheimer’s disease; Thoraflex Hybrid Device Implantation in the United States; FDA 510(k) Clearance for the DABRA 2.0 Catheter
Collagen Matrix received FDA 510(k) approval for Fibrillar Collagen Wound Dressing On June 29, 2022, Collagen Matrix, Inc., a leader in regenerative medicine, a global manufacturer of collagen and other biomaterial-based medical devices, and Linden Capital Partners portfolio company announced FDA 510(k) Clearan...
Read More...
Jul 31, 2025
Understanding How Cardiac Devices are Aiding in Treatment and Prevention of Heart Disease
Cardiovascular diseases (CVDs) continue to dominate as the leading global cause of death, responsible for approximately 17.9 million deaths annually, as reported by the World Health Organization (2021). Representing the highest disease burden worldwide, CVD incidence is rising rapidly across most low- and middle-in...
Read More...
Jul 05, 2022
AstraZeneca’s Imfinzi Shows Positive Results; Novartis Announces Results of Tislelizumab; FDA Grants Orphan Drug Designation to Evorpacept; EU Approves Sanofi’s Xenpozyme; Bayer’s Kerendia Approves in China; FDA Breakthrough Therapy Designation to Talquetamab; FDA Puts Clinical Hold on Sanofi’s Tolebrutinib; FDA Rejects Spero’s Tebipenem
FDA Grants Orphan Drug Designation to Evorpacept for AML ALX Oncology Holdings announced that the U.S. Food and Drug Administration had granted orphan drug designation to Evorpacept, a next-generation CD47 blocker, for treating patients with acute myeloid leukemia (AML). Acute Myeloid Leukemia (AML) is an agg...
Read More...
Jul 04, 2022
NexoBrid and its Awaiting US Approval
A Burn takes place when the skin comes into contact with a heat source. Burns can occur from many different sources. The most common sources that cause Burns are fire/flame, scalds, hot objects, electrical, and chemical agents, respectively. Burns is a common injury seen in emergency departments around the world. E...
Read More...
Jul 01, 2022
Chlamydia Treatment: Is it the End of the Antibiotic Era?
Chlamydia is the most common bacterial sexually transmitted infection across the world. Chlamydia infection is asymptomatic in 50-88% of men and women, and 46% of infections resolve spontaneously after a year. In women, persistent chlamydia infection can cause pelvic inflammatory disease, ectopic pregnancy, tubal i...
Read More...
Jun 30, 2022
LumiThera’s US LIGHTSITE III Trial; First Patient Enrolled in Vascular Closure Device Study of Teleflex; Varian’s Flash Technology Clinical Trial, FAST-02; 3Spine’s MOTUS Device; Illumina’s Research Test to Detect Tumor Genome; Acutus Medical’s AcQCross Qx System
LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda® Light Delivery System On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) t...
Read More...